Literature DB >> 9551960

Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells.

M F Bachmann1, P Waterhouse, D E Speiser, K McKall-Faienza, T W Mak, P S Ohashi.   

Abstract

CTLA-4 has been proposed to negatively regulate immune responses, and mice deficient for CTLA-4 expression succumb to a lymphoproliferative disorder within a few weeks after birth. This study assessed the responsiveness of CTLA-4-deficient T cells expressing a class I-restricted TCR specific for lymphocytic choriomeningitis virus (LCMV). The kinetics of T cell proliferation were studied in vitro after stimulation of T cells with full and partial T cell agonists. No gross abnormalities in CTLA-4-deficient T cells could be detected. Using adoptive transfer experiments, T cell responses were also measured in vivo after infection with LCMV. Low dose infection with LCMV leads to strong expansion of specific T cells followed by a reduction in T cells that parallels the elimination of Ag. The kinetics of T cell expansion and elimination after low dose LCMV infection were not affected by the absence of CTLA-4. High dose infection of mice with LCMV leads to a transient expansion of T cells followed by T cell exhaustion, where all specific T cells are eliminated. T cell exhaustion also occurred in the absence of CTLA-4. Thus, surprisingly, the absence of CTLA-4 did not interfere with T cell activation, down-regulation of ongoing T cell responses after the elimination of Ag, or the exhaustion of T cell responses in the presence of excessive amounts of Ag.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551960

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 2.  CTLA-4 and tolerance: the biochemical point of view.

Authors:  Shunsuke Chikuma; Jeffrey A Bluestone
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  Acquisition of antigen presentasome (APS), an MHC/costimulatory complex, is a checkpoint of memory T-cell homeostasis.

Authors:  Sven Mostböck; Marta Catalfamo; Yutaka Tagaya; Jeffrey Schlom; Helen Sabzevari
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

4.  The Foxo and the hound: chasing the in vivo regulation of T cell populations during infection.

Authors:  Elia D Tait; Christopher A Hunter
Journal:  Nat Immunol       Date:  2009-05       Impact factor: 25.606

5.  VSIG4, a B7 family-related protein, is a negative regulator of T cell activation.

Authors:  Lorenz Vogt; Nicole Schmitz; Michael O Kurrer; Monika Bauer; Heather I Hinton; Silvia Behnke; Dominique Gatto; Peter Sebbel; Roger R Beerli; Ivo Sonderegger; Manfred Kopf; Philippe Saudan; Martin F Bachmann
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

6.  Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell.

Authors:  James E D Thaventhiran; Anja Hoffmann; Lukasz Magiera; Maike de la Roche; Holger Lingel; Monika Brunner-Weinzierl; Douglas T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-27       Impact factor: 11.205

Review 7.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

8.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.

Authors:  Lucy S K Walker; David M Sansom
Journal:  Nat Rev Immunol       Date:  2011-11-25       Impact factor: 53.106

Review 9.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Authors:  John Attanasio; E John Wherry
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor.

Authors:  P Scheipers; H Reiser
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.